Evidence map›Paper›PMID 35008796›Full record

ReviewInternational journal of molecular sciences2021

The p38 MAPK Components and Modulators as Biomarkers and Molecular Targets in Cancer.

Laura García-Hernández, María Belén García-Ortega, Gloria Ruiz-Alcalá, Esmeralda Carrillo, Juan Antonio Marchal, María Ángel García

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 95 citations in OpenAlex.

  1. METTL14-Mediated lncRNA MSTRG.292666.16 mInternational journal of molecular sciences · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. New Phenylpropanoid fromCurrent pharmaceutical design · 2026
    Review
  12. Review
  13. International journal of molecular sciences · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Role of signaling pathways in endometrial cancer.Molecular biology reports · 2025
    Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Laura García-HernándezFaculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain.ORCID 0000-0002-0827-2620
María Belén García-OrtegaBiopathology and Regenerative Medicine Institute (IBIMER), Centre for Biomedical Research (CIBM), University of Granada, 18100 Granada, Spain.
Gloria Ruiz-AlcaláBiopathology and Regenerative Medicine Institute (IBIMER), Centre for Biomedical Research (CIBM), University of Granada, 18100 Granada, Spain.
Esmeralda CarrilloBiopathology and Regenerative Medicine Institute (IBIMER), Centre for Biomedical Research (CIBM), University of Granada, 18100 Granada, Spain.ORCID 0000-0002-5551-4389
Juan Antonio MarchalBiopathology and Regenerative Medicine Institute (IBIMER), Centre for Biomedical Research (CIBM), University of Granada, 18100 Granada, Spain.ORCID 0000-0002-4996-8261
María Ángel GarcíaBiopathology and Regenerative Medicine Institute (IBIMER), Centre for Biomedical Research (CIBM), University of Granada, 18100 Granada, Spain.ORCID 0000-0003-2003-3769
Universidad de Granada · ESUniversidad Complutense de Madrid · ES

Funding

MCIN/AEI/10.13039/501100011033/FEDER RTI2018-101309-B-C22
6 · The paper itself

Abstract

The mitogen-activated protein kinase (MAPK) family is an important bridge in the transduction of extracellular and intracellular signals in different responses at the cellular level. Within this MAPK family, the p38 kinases can be found altered in various diseases, including cancer, where these kinases play a fundamental role, sometimes with antagonistic mechanisms of action, depending on several factors. In fact, this family has an immense number of functionalities, many of them yet to be discovered in terms of regulation and action in different types of cancer, being directly involved in the response to cancer therapies. To date, three main groups of MAPKs have been identified in mammals: the extracellular signal-regulated kinases (ERK), Jun N-terminal kinase (JNK), and the different isoforms of p38 (α, β, γ, δ). In this review, we highlight the mechanism of action of these kinases, taking into account their extensive regulation at the cellular level through various modifications and modulations, including a wide variety of microRNAs. We also analyze the importance of the different isoforms expressed in the different tissues and their possible role as biomarkers and molecular targets. In addition, we include the latest preclinical and clinical trials with different p38-related drugs that are ongoing with hopeful expectations in the present/future of developing precision medicine in cancer.

Indexed as

Molecular Targeted TherapyAnimalsBiomarkers, TumorClinical Trials as TopicHumansNeoplasmsp38 Mitogen-Activated Protein KinasesSubstrate SpecificityBiomarkers, Tumorp38 Mitogen-Activated Protein KinasesbiomarkerscancerisoformskinasesMAPKp38therapy

Identifiers

PMID35008796
PMCPMC8745478
OpenAlexW4200339324

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.